GR3031105T3 - Substituted azetidinone compounds useful as hypocholesterolemic agents - Google Patents

Substituted azetidinone compounds useful as hypocholesterolemic agents

Info

Publication number
GR3031105T3
GR3031105T3 GR990402188T GR990402188T GR3031105T3 GR 3031105 T3 GR3031105 T3 GR 3031105T3 GR 990402188 T GR990402188 T GR 990402188T GR 990402188 T GR990402188 T GR 990402188T GR 3031105 T3 GR3031105 T3 GR 3031105T3
Authority
GR
Greece
Prior art keywords
aryl
lower alkyl
substituted
alkyl
coor6
Prior art date
Application number
GR990402188T
Other languages
English (en)
Inventor
Michael P Kirkup
Sundeep Dugar
Banderpalle B Shankar
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of GR3031105T3 publication Critical patent/GR3031105T3/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/30Preparation of optical isomers
    • C07C227/32Preparation of optical isomers by stereospecific synthesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GR990402188T 1994-03-25 1999-08-27 Substituted azetidinone compounds useful as hypocholesterolemic agents GR3031105T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21849894A 1994-03-25 1994-03-25
PCT/US1995/003196 WO1995026334A1 (en) 1994-03-25 1995-03-22 Substituted azetidinone compounds useful as hypocholesterolemic agents

Publications (1)

Publication Number Publication Date
GR3031105T3 true GR3031105T3 (en) 1999-12-31

Family

ID=22815366

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990402188T GR3031105T3 (en) 1994-03-25 1999-08-27 Substituted azetidinone compounds useful as hypocholesterolemic agents

Country Status (20)

Country Link
US (2) US5627176A (el)
EP (1) EP0751934B1 (el)
JP (1) JP3524927B2 (el)
KR (1) KR100338171B1 (el)
CN (1) CN1144522A (el)
AT (1) ATE183738T1 (el)
AU (1) AU686361B2 (el)
CA (1) CA2186364C (el)
CZ (1) CZ281596A3 (el)
DE (1) DE69511687T2 (el)
DK (1) DK0751934T3 (el)
ES (1) ES2135050T3 (el)
FI (1) FI963817A0 (el)
GR (1) GR3031105T3 (el)
HU (1) HU221309B1 (el)
NO (1) NO964008L (el)
NZ (1) NZ283528A (el)
PL (1) PL316431A1 (el)
SK (1) SK119796A3 (el)
WO (1) WO1995026334A1 (el)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
PT877750E (pt) 1995-10-31 2002-09-30 Schering Corp 2-azetidinonas substituidas por acucar uteis como agentes hipocolesterolemiantes
AU7472896A (en) * 1995-11-02 1997-05-22 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
WO2000063703A1 (en) 1999-04-16 2000-10-26 Schering Corporation Use of azetidinone compounds
US6584357B1 (en) * 2000-10-17 2003-06-24 Sony Corporation Method and system for forming an acoustic signal from neural timing difference data
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
RU2297422C2 (ru) * 2000-12-20 2007-04-20 Шеринг Корпорейшн Замещенные остатком сахара 2-азетидиноны, пригодные для использования в качестве гипохолестеринемических препаратов
AR035533A1 (es) 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
SK9502003A3 (en) * 2001-01-26 2003-12-02 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156445A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
AU2005246926B2 (en) * 2001-01-26 2008-02-28 Merck Sharp & Dohme Corp. The use of substituted azetidinone compounds for the treatment of sitosterolemia
EE05453B1 (et) 2001-03-28 2011-08-15 Schering Corporation Protsess asetidinoonvahehendite valmistamiseks
EP1859796A3 (en) * 2001-09-21 2008-07-02 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US20040132058A1 (en) 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
EP1601668B1 (en) 2003-03-07 2008-08-27 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2517572C (en) * 2003-03-07 2011-12-13 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
JP2007510659A (ja) * 2003-11-05 2007-04-26 シェーリング コーポレイション 脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置
EP1699759B1 (en) 2003-12-23 2010-10-20 AstraZeneca AB Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
CN100471835C (zh) * 2003-12-23 2009-03-25 默克公司 抗高胆固醇血症化合物
WO2005069900A2 (en) * 2004-01-16 2005-08-04 Merck & Co., Inc. Npc1l1 (npc3) and methods of identifying ligands thereof
WO2006039334A1 (en) * 2004-09-29 2006-04-13 Schering Corporation Combinations of substituted azetidonones and cb1 antagonists
CN101115726A (zh) 2004-12-03 2008-01-30 先灵公司 作为cb1拮抗剂的取代哌嗪
DE602006010870D1 (de) * 2005-06-20 2010-01-14 Schering Corp Als antagonisten von histamin h3 geeignete piperidinderivate
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR059021A1 (es) 2006-01-18 2008-03-05 Schering Corp Moduladores de receptores cannabinoides
EP1986489A2 (en) 2006-02-24 2008-11-05 Schering Corporation Npc1l1 orthologues
WO2007103453A1 (en) * 2006-03-06 2007-09-13 Teva Pharmaceutical Industries Ltd. Ezetimibe compositions
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
JPWO2008108486A1 (ja) 2007-03-06 2010-06-17 帝人ファーマ株式会社 1−ビアリールアゼチジノン誘導体
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
US20090047716A1 (en) * 2007-06-07 2009-02-19 Nurit Perlman Reduction processes for the preparation of ezetimibe
US20100286160A1 (en) * 2007-06-28 2010-11-11 Intervet Inc. Substituted piperazines as cb1 antagonists
US8623873B2 (en) * 2007-06-28 2014-01-07 Intervet Inc. Substituted piperazines as CB1 antagonists
US20090093627A1 (en) * 2007-08-30 2009-04-09 Lorand Szabo Process for preparing intermediates of ezetimibe by microbial reduction
CN101200443B (zh) * 2007-10-17 2011-06-29 中国药科大学 氮杂环丁酮衍生物、其制备方法及含有它们的药物组合
CA2754384A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
CN101993403B (zh) * 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
MX365046B (es) 2012-05-01 2019-05-17 Althera Life Sciencies Llc Formulacion de tableta oral que consiste de una combinacion fija de rosuvastatina y ezetimiba para el tratamiento de hiperlipidemia y enfermedades cardiovasculares.
JP5969958B2 (ja) * 2013-06-27 2016-08-17 国立大学法人お茶の水女子大学 光学活性含フッ素アミノ酸類の製造方法
CN105294426B (zh) 2014-06-09 2019-05-14 浙江海正药业股份有限公司 氮杂环丁酮化合物制备方法及其中间体
CN104860980B (zh) * 2015-04-23 2018-06-19 上海弈柯莱生物医药科技有限公司 一种用于合成依折麦布的中间体及其制备方法和应用
BR112019015107A2 (pt) 2017-01-23 2020-03-10 Dong Wha Pharm. Co., Ltd. Formulação de complexo compreendendo inibidor de hmg-coa redutase e clopidogrel

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4803266A (en) * 1986-10-17 1989-02-07 Taisho Pharmaceutical Co., Ltd. 3-Oxoalkylidene-2-azetidinone derivatives
IL89835A0 (en) * 1988-04-11 1989-12-15 Merck & Co Inc Substituted azetidinones,their preparation and pharmaceutical compositions containing them
JPH02268144A (ja) * 1989-04-11 1990-11-01 Ube Ind Ltd β―アミノエステルの製造法
US4983597A (en) * 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
ES2107548T3 (es) * 1991-07-23 1997-12-01 Schering Corp Compuestos de beta-lactama sustituidos utiles como agentes hipocolesterolemicos y procedimientos para su preparacion.

Also Published As

Publication number Publication date
CN1144522A (zh) 1997-03-05
AU2159695A (en) 1995-10-17
NO964008D0 (no) 1996-09-24
NO964008L (no) 1996-11-22
DE69511687T2 (de) 2000-03-16
KR970702246A (ko) 1997-05-13
JPH09510970A (ja) 1997-11-04
HU221309B1 (en) 2002-09-28
AU686361B2 (en) 1998-02-05
HU9602616D0 (en) 1996-11-28
CA2186364C (en) 2008-12-30
DK0751934T3 (da) 1999-12-13
US5688990A (en) 1997-11-18
CA2186364A1 (en) 1995-10-05
SK119796A3 (en) 1997-05-07
FI963817A7 (fi) 1996-09-25
HUT74887A (en) 1997-02-28
EP0751934B1 (en) 1999-08-25
US5627176A (en) 1997-05-06
WO1995026334A1 (en) 1995-10-05
CZ281596A3 (en) 1997-05-14
ATE183738T1 (de) 1999-09-15
NZ283528A (en) 1997-12-19
ES2135050T3 (es) 1999-10-16
PL316431A1 (en) 1997-01-06
KR100338171B1 (ko) 2002-11-23
JP3524927B2 (ja) 2004-05-10
DE69511687D1 (de) 1999-09-30
MX9604030A (es) 1997-09-30
EP0751934A1 (en) 1997-01-08
FI963817A0 (fi) 1996-09-25

Similar Documents

Publication Publication Date Title
GR3031105T3 (en) Substituted azetidinone compounds useful as hypocholesterolemic agents
TW427974B (en) Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
NO308468B1 (no) Svovelsubstituerte azetidinonforbindelser som er anvendbare som hypokolesterolemiske midler
JP4351842B2 (ja) 低コレステロール血症剤として有用な糖置換2−アゼチジノン
ES2266459T3 (es) Uso de compuestos de azetidinona sustituidos para el tratamiento de sitosterolemia.
US5688785A (en) Substituted azetidinone compounds useful as hypocholesterolemic agents
MX9606319A (es) Compuestos de acetidinonas sustituidas utiles como agentes hipocolesterolemicos.
AR035739A1 (es) Composiciones farmaceuticas y combinaciones terapeuticas que comprenden secuestrante (s) de los acidos biliares y de inhibidor (es) de la absorcion de los esteroles y el uso de dichas composiciones para la manufactura de un medicamento para el tratamiento de indicaciones vasculares
IL133623A0 (en) Antithrombotic agents
IL133627A0 (en) Antithrombotic agents
MY130668A (en) Isothiazole derivatives useful as anticancer agents
AR034204A1 (es) Composiciones y combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y el uso de los mismos para preparar medicamentos para el tratamiento para indicaciones vasculares
HUT75865A (en) Tropane-2-aldoxime derivatives pharmaceutical compositions containing them, process for producing them and their use
JP2003026673A (ja) 骨形成促進剤
PL312788A1 (en) Benzopyranes and pharmaceutical compounds containing them
EP0937458A3 (en) Pyrrolidine and piperidine derivatives
AU5125798A (en) Novel n-benzenesulphonyl-l-proline derivatives, method for preparing and therapeutic use
RU94022744A (ru) Производные 5-амино-8-метил-7-пирролидинилхинолин-3-карбоновой кислоты, способы их получения, фармацевтическая композиция, способ лечения, промежуточный продукт
RU99111733A (ru) Производные замещенной 4-бифенил-4-гидроксимасляной кислоты, используемые в качестве ингибиторов матричной металлопротеазы